Hologic

Hologic has entered into a definitive agreement to sell Cynosure to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Under the terms of the agreement, approximately 825 employees will transfer with the Cynosure business. The transaction is expected to close around the end of calendar 2019, subject to regulatory approvals and other customary conditions.

Hologic, a device manufacturer specializing in women’s health and parent company to Cynosure, has acquired approximately 46 percent of SuperSonic Imagine, a company that specializes in ultrasound medical imaging.

SuperSonic Imagine’s main shareholders, namely Bpifrance, Andera Partners, Auriga Partners, Mérieux Participations and CDC PME Croissance, holding together 10,841,409 shares, representing approximately 46 percent of the outstanding share capital of SuperSonic Imagine, sold all of their shares to Hologic at a price of €1.50 per share.

Hologic, parent company of Cynosure, opened its first Learning and Experience Centre in Zaventem, Belgium in March. The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) regions.

The 1,500-square-meter facility contains fully equipped training labs with demonstration capabilities for technologies from all four of Hologic’s divisions (Breast & Skeletal Health, Diagnostic, Gynecological Surgical and Medical Aesthetics) to provide hands-on training and experience.

Hologic—a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products—and laser manufacturer Cynosure have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, for a total cost of approximately $1.65 billion. The boards of directors of both companies have approved the transaction unanimously.